| Title |
New Class of Monoclonal Antibodies against Severe Influenza: Prophylactic and Therapeutic Efficacy in Ferrets
|
|---|---|
| Published in |
PLOS ONE, February 2010
|
| DOI | 10.1371/journal.pone.0009106 |
| Pubmed ID | |
| Authors |
Robert H. E. Friesen, Wouter Koudstaal, Martin H. Koldijk, Gerrit Jan Weverling, Just P. J. Brakenhoff, Peter J. Lenting, Koert J. Stittelaar, Albert D. M. E. Osterhaus, Ronald Kompier, Jaap Goudsmit |
| Abstract |
The urgent medical need for innovative approaches to control influenza is emphasized by the widespread resistance of circulating subtype H1N1 viruses to the leading antiviral drug oseltamivir, the pandemic threat posed by the occurrences of human infections with highly pathogenic avian H5N1 viruses, and indeed the evolving swine-origin H1N1 influenza pandemic. A recently discovered class of human monoclonal antibodies with the ability to neutralize a broad spectrum of influenza viruses (including H1, H2, H5, H6 and H9 subtypes) has the potential to prevent and treat influenza in humans. Here we report the latest efficacy data for a representative antibody of this novel class. |
Mendeley readers
The data shown below were compiled from readership statistics for 91 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 1% |
| Greece | 1 | 1% |
| Denmark | 1 | 1% |
| Unknown | 88 | 97% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 33 | 36% |
| Student > Ph. D. Student | 13 | 14% |
| Student > Bachelor | 11 | 12% |
| Student > Master | 10 | 11% |
| Other | 5 | 5% |
| Other | 16 | 18% |
| Unknown | 3 | 3% |
| Readers by discipline | Count | As % |
|---|---|---|
| Agricultural and Biological Sciences | 41 | 45% |
| Medicine and Dentistry | 10 | 11% |
| Biochemistry, Genetics and Molecular Biology | 10 | 11% |
| Immunology and Microbiology | 9 | 10% |
| Pharmacology, Toxicology and Pharmaceutical Science | 3 | 3% |
| Other | 12 | 13% |
| Unknown | 6 | 7% |